surmount-1 tirzepatide three year efficacy outcomes just presented at #ObesityWeek2024 ๐ ๐Sustained weight loss of 22.9% or an average 54lbs over 3 years ๐ฝ94% reduction in risk of progression to diabetes. Number Presented today at #ECO2026 โคต๏ธ
Pay in 4 interest-free payments of $6.86 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Aug 1 - Aug 6
Live Spec
Presented today at #ECO2026 The SURMOUNT MAINTAIN trial found that continuing tirzepatide at the maximum tolerated dose maintained bodyweight reduction and health related benefits in adults with obesity. Explore the research: https: t.co RjLxWa5qjV SURMOUNT 2: Tirzepatide achieved up to 15.7% weight loss SURMOUNT1 study design. This is a phase 3, multicenter, randomized, Download Scientific Diagram SURPASS to SURMOUNT: The Tirzepatide Trials To Know
Store: starnailspa.net ยท Domain: starnailspa.net






















